Find policies, billing codes, payers, states, and providers
HCPCS J1412: Valoctocogene Roxaparvovec Gene Therapy Injection
HCPCS Level II code J1412 identifies an injectable formulation of valoctocogene roxaparvovec-rvox, a gene therapy product specified per milliliter with a nominal 2 x 10^13 vector genomes. As an HCPCS Level II biologic code for a high-cost, specialty gene therapy, it matters nationally for payer coverage policies, prior authorization workflows, and site-of-service planning given the complexity and cost of administration.
Key payers in the national discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what this code represents clinically, typical settings where the product is administered, and the implications for billing and policy. The publication includes benchmarking of payer coverage approaches, common billing modifiers and claim considerations, and context on clinical use and coding relationships where available.
This summary is intended to orient clinical billing teams, revenue cycle professionals, and policy analysts to the primary coding and care-delivery considerations tied to J1412, and to highlight areas where payer policy and administration processes are commonly applied. Data not available in the input is noted where relevant in detailed sections.
Customize your policy alerts
Sign up for hcpcs J1412 policy alerts
Get alerted when payer policies referencing J1412 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J1412 describes an injection of valoctocogene roxaparvovec-rvox per milliliter, containing nominal 2 x 10^13 vector genomes. This entry represents a gene therapy product supplied for intravenous or intramuscular administration as an injectable biologic.
Service type: Gene therapy injection administered as a one-time or limited series biologic treatment intended to deliver a viral vector carrying therapeutic genetic material.
Typical site of service: Hospital outpatient infusion center, specialty infusion clinic, or ambulatory surgical center equipped to handle advanced biologic and gene therapy administration.